Rein Therapeutics Expands Phase 2 RENEW Trial Across Five Countries
Austin, Texas, USA | July 21, 2026 Rein Therapeutics announced that its Phase 2 RENEW clinical trial evaluating the...
idiopathic pulmonary fibrosis
Advertisement
Boehringer Reports Strong H1 2026 Sales
INGELHEIM, Germany, July 15, 2026 Boehringer Ingelheim reported strong financial and operational performance for the first half of 2026,...
Syndax Unveils SNDX-4321, Expands Pipeline
NEW YORK, July 14, 2026 Syndax Pharmaceuticals unveiled two new pipeline candidates during its 2026 R&D Event, expanding its...
Celea Doses First Patient in Phase 3 SURPASS-IPF Trial
BOSTON, July 13, 2026 Celea Therapeutics announced that the first patient has been dosed in the global Phase 3...
Insilico Begins Phase III Trial of AI-Designed IPF Therapy
CAMBRIDGE, Mass., July 7, 2026 Insilico Medicine has announced the initiation of its Phase III clinical trial evaluating Rentosertib,...
Advertisements
Contineum Therapeutics Publishes PIPE-791 Discovery Study
SAN DIEGO, June 30, 2026 Contineum Therapeutics, Inc. announced the publication of its scientific manuscript describing the discovery and...
GRI Bio Secures FDA Orphan Drug Designation for GRI-0621 in IPF
LA JOLLA, Calif., June 18, 2026 GRI Bio, Inc. announced that the U.S. Food and Drug Administration (FDA) has...
Boehringer Ingelheim Reports Survival Gains With Nerandomilast
INGELHEIM, Germany, June 18, 2026 Boehringer Ingelheim has announced new long-term survival modeling analyses from its pivotal Phase III...
Rein Therapeutics Expands Phase 2 RENEW Trial into the UK
AUSTIN, Texas, June 11, 2026 Rein Therapeutics, Inc. (NASDAQ: RNTX) announced the expansion of its ongoing Phase 2 RENEW...
Oorja Bio Reports Positive Phase 1 Data for ORJ-001 in IPF
HOUSTON, Texas, May 19, 2026 Oorja Bio announced positive first-in-human Phase 1 clinical data for ORJ-001, a first-in-class peptide...
Advertisement
